Investors Unite in Class Action Lawsuit Against MoonLake Immunotherapeutics
NEW YORK – Levi & Korsinsky, LLP has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics (NASDAQ: MLTX). This legal action addresses concerns regarding potential securities fraud impacting the company and its loyal investors.
Understanding the Class Action
This class action lawsuit aims to recover losses suffered by investors who held shares in MoonLake during the specified timeframe of March 10, 2024 to September 29, 2025. If your investment was affected during that period, it is essential to understand the details of this action.
Defining the Allegations
The complaint filed points out several critical allegations against the defendants related to misleading statements and omitted information regarding the company's key drug candidate, SLK. It is alleged that: (1) SLK and BIMZELX share molecular targets, which undermines claims of SLK's effectiveness; (2) SLK's unique Nanobody structure may not provide the benefits asserted over the existing monoclonal antibody, BIMZELX; (3) The supposed enhanced tissue penetration of SLK does not equate to improved clinical outcomes; and (4) These factors lead to a significant misleading of investors about SLK’s true potential.
What Investors Should Do Next
If you have incurred financial losses from your investments in MoonLake, it's important to note that the deadline to request to be appointed as lead plaintiff is approaching. Investors have until December 15, 2025, to make their voices heard. However, participation in any recovery does not require acting as a lead plaintiff.
No Fees for Participation
For those involved in the class, compensation may be accessible without incurring any costs. This presents a chance for investors to seek restitution with no upfront fees or financial liability.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has built a reputation over the past two decades, successfully recovering hundreds of millions of dollars for shareholders. Their experienced legal team specializes in complex securities litigation, equipped with over 70 professionals dedicated to supporting their clients. They have consistently been recognized in ISS Securities Class Action Services' Top 50 Report, affirming their status as a leading firm in securities litigation in the United States.
Contact Information
For further inquiries regarding the lawsuit or for assistance, you can reach the team at Levi & Korsinsky:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Email: [email protected]
Website: www.zlk.com
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The lawsuit aims to recover losses for investors who were affected by alleged securities fraud related to MoonLake Immunotherapeutics.
What are the main allegations in the lawsuit?
The allegations include claims of false statements about SLK's effectiveness compared to BIMZELX and misleading investors regarding its clinical potential.
What should I do if I lost money in my investment?
If you lost money between March 10, 2024, and September 29, 2025, you can request to be a lead plaintiff up to December 15, 2025.
Are there any costs to participate in the lawsuit?
No, there are no up-front costs or fees to participate in this class action.
How does Levi & Korsinsky support investors?
Levi & Korsinsky has extensive experience in securities litigation, helping recover millions for affected investors and providing legal expertise to navigate the lawsuit.
